Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The HIV integrase (IN) strand transfer inhibitor (INSTI) bictegravir (BIC) has a long dissociation half-life ( t 1/2 ) from wild-type IN-DNA complexes: BIC 163 h > dolutegravir (DTG) 96 h > raltegravir (RAL) 10 h > elvitegravir (EVG) 3.3 h. In cells, BIC had more durable antiviral activity against wild-type HIV after drug washout than RAL or EVG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Thus, the dissociation half-times of dolutegravir and bictegravir from the wild-type HIV-1 intasome were reported to be ~100 and 160 h, respectively164,165.”
From Structure and function of retroviral integrase (2022) · cites this paper as [165]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057 · cited 1×
“INSTIs were docked using Glide XP docking protocol with expanded sampling method (25).”
MethodA hierarchical approach to all‐atom protein loop prediction
Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J. F., Honig, B., Shaw, D. E., & Friesner, R. A. (2004) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10613 · Cited by 2,504
Bioisosterism: A Rational Approach in Drug Design
Patani, G. A., & LaVoie, E. J. (1996) · Chemical Reviews · doi:10.1021/cr950066q · Cited by 1,328
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Swindells, S., Andrade-Villanueva, J.-F., Richmond, G. J., Rizzardini, G., Baumgarten, A., Masiá, M., Latiff, G., Pokrovsky, V., Bredeek, F., Smith, G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1904398 · Cited by 594
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Orkin, C., Arasteh, K., Górgolas Hernández-Mora, M., Pokrovsky, V., Overton, E. T., Girard, P.-M., Oka, S., Walmsley, S., Bettacchi, C., Brinson, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1909512 · Cited by 487
Tsiang, M., Jones, G. S., Goldsmith, J., Mulato, A., Hansen, D., Kan, E., Tsai, L., Bam, R. A., Stepan, G., Stray, K. M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01474-16 · Cited by 290
Self-citationLesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Hightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00157-11 · Cited by 226
HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
Blanco, J.-L., Varghese, V., Rhee, S.-Y., Gatell, J. M., & Shafer, R. W. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir025 · Cited by 218
Research works printed but not linked: 1
- Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Underwood M, Pappa KA, Smith KY, Gartland M, Aboud M, van Wyk J, Wynne B. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection—3-year results from the Gemini studies, poster 018. HIV Glasgow, 5 to 8 October 2020.
Cited by
Zhao, A., Crutchley, R. D., Guduru, R. C., Ton, K., Lam, T., & Min, A. (2022) · Retrovirology · doi:10.1186/s12977-022-00608-1 · Cited by 156
Structure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective
Carr, A., Mackie, N., Paredes, R., & Ruxrungtham, K. (2023) · Antiviral Therapy · doi:10.1177/13596535231201162 · Cited by 89
Moranguinho, I., Taveira, N., & Bártolo, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065905 · Cited by 37
Biktarvy for the treatment of HIV infection: Progress and prospects
Clercq, E. D., Zhang, Z., Huang, J., Zhang, M., & Li, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115862 · Cited by 36
Advances in the development of HIV integrase strand transfer inhibitors
Wang, Y., Gu, S., He, Q., & Fan, R. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113787 · Cited by 29
Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
Richetta, C., Tu, N. Q., & Delelis, O. (2022) · Viruses · doi:10.3390/v14122591 · Cited by 24
Azzman, N., Gill, M. S. A., Hassan, S. S., Christ, F., Debyser, Z., Mohamed, W. A. S., & Ahemad, N. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2529 · Cited by 24
New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs
Marra, M., Catalano, A. A., Sinicropi, M. S., Ceramella, J., Iacopetta, D., Salpini, R., Svicher, V., Marsico, S., Aquaro, S., & PELLEGRINO, M. A. (2024) · Viruses · doi:10.3390/v16091484 · Cited by 22
Retroviral integrase: Structure, mechanism, and inhibition
Passos, D. O., Li, M., Craigie, R., & Lyumkis, D. (2021) · The Enzymes · doi:10.1016/bs.enz.2021.06.007 · Cited by 22
Sellem, B., Abdi, B., Lê, M., Tubiana, R., Valantin, M., Seang, S., Schneider, L., Fayçal, A., Peytavin, G., Soulié, C., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040583 · Cited by 22
Sayyed, S. K., Quraishi, M., Jobby, R., Rameshkumar, N., Kayalvizhi, N., Krishnan, M., & Sonawane, T. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03461-8 · Cited by 15
Andreatta, K. N., D’Antoni, M. L., Chang, S., Parvangada, A., Martin, R., Blair, C. J., Hagins, D. P., Kumar, P. N., Hindman, J. T., Martin, H., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29899 · Cited by 14
Andreatta, K. N., Sax, P. E., Wohl, D., D’Antoni, M. L., Liu, H., Hindman, J. T., & Callebaut, C. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae407 · Cited by 14
Acosta, R. K., D’Antoni, M. L., Mulato, A. S., Yant, S. R., Cihlář, T., & White, K. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02038-21 · Cited by 12
Self-citationExpanding therapeutic options: lenacapavir + bictegravir as a potential treatment for HIV
Doan, J., Brunzo-Hager, S., Satterly, B., & Cory, T. J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2294918 · Cited by 12
Weld, E. D., Beattie, T., Moodley, J., Mapendere, M., Salles, I., Solans, B. P., Nonyane, B. A. S., Wiesner, L., Nielson, T., Edward, V., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(25)00002-5 · Cited by 10
Arora, P., Liu, H., Ling, J. R., Hindman, J. T., & Marathe, D. D. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70061 · Cited by 9
Naidoo, A., Dooley, K. E., Naidoo, K., Padayatchi, N., Yende‐Zuma, N., Perumal, R., Dorse, G., Boodhram, R., & Osuala, E. C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-067765 · Cited by 9
Brief Histories of Retroviral Integration Research and Associated International Conferences
Grandgenett, D. P., & Engelman, A. (2024) · Viruses · doi:10.3390/v16040604 · Cited by 8
Rashid, I., Unger, N. R., Willis, C., Dhippayom, T., Ramgopal, M. N., Sherman, E. M., Yared, N. F., Safran, R., Swiatlo, E., Weinberg, A. R., et al. (2025) · HIV Medicine · doi:10.1111/hiv.70050 · Cited by 6
Arora, P., Hindman, J. T., West, S., Ling, J. R., Palaparthy, R., & Marathe, D. D. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00781-25 · Cited by 6
Sun, S. A., Nikanjam, M., Mirochnick, M. H., Powis, K. M., Eke, A. C., Stek, A. M., Arora, P., Cressey, T. R., Brooks, K. M., Best, B. M., et al. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70134 · Cited by 6
Naidoo, A., Naidoo, K., Letsoalo, M. P., Wasmann, R. E., Dorse, G., Perumal, R., Moosa, M. S., Osuala, E. C., Boodhram, R., Chimukangara, B., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(25)00200-0 · Cited by 4
Perri, G. D. (2023) · PubMed Central · doi:10.53854/liim-3103-3 · Cited by 4
Brar, I., Ruane, P. J., Berhe, M., Brinson, C. C., Benson, P. M., Henry, K., Liu, H., Andreatta, K. N., Hindman, J. T., & Ramgopal, M. N. (2025) · Medicine · doi:10.1097/md.0000000000041482 · Cited by 4
Lemaitre, F., Lagoutte‐Renosi, J., Gagnieu, M., Parant, F., Venisse, N., Grégoire, M., Bouchet, S., Garraffo, R., Lê, M., Muret, P., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15890 · Cited by 3
Boopathy, A. V., D'Antoni, M. L., Andreatta, K., Chang, S., Hindman, J. T., & Callebaut, C. (2025) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003742 · Cited by 1
Иосифович, Ш. В., & Мацкеплишвили, С. Т. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.04.203157 · Cited by 1
Twice‐daily bictegravir during rifampicin‐based tuberculosis therapy: A pragmatic alternative
Sánchez-Cano, J. G., Muñoz-Echeverría, L., Casco‐García, M., & Moreno-Núñez, L. (2026) · HIV Medicine · doi:10.1111/hiv.70245 · Cited by 1
Non-integrase mechanisms for dolutegravir resistance
Engelman, A. (2026) · Retrovirology · doi:10.1186/s12977-026-00678-5 · Cited by 1
Targeting HIV-1 integrase: A review of options, challenges and future directions
Bourquin, R. A., & Schaeffer, P. M. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153092 · Cited by 1
Abé, E., Landman, R., Assoumou, L., Amat, K. K. A., Lambert-Niclot, S., Bellet, J., Gibowski, S., Girard, P., Morand‐Joubert, L., de Truchis, P., et al. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae112 · Cited by 1
The need to avert emergent resistance to dolutegravir in children and adolescents with HIV
BRENNER, B. G., & Fairlie, L. (2025) · AIDS · doi:10.1097/qad.0000000000004081
Self-citationEffectiveness of B/F/TAF in adults with HIV who are viremic with M184V/I
Rolle, C.-P., D’Antoni, M. L., Corales, R. B., Marongiu, A., Gruber, J., Schreibman, T., Bell, D., Hsiao, C.-B., & Brar, I. (2025) · AIDS Research and Therapy · doi:10.1186/s12981-025-00795-9
HIV-1 Integrase During the Time: History of Drugs and Effort for the New Inhibitors’ Identification
Esposito, F., Saccoliti, F., Patacchini, E., & Santo, R. D. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_180
Zou, X., Zhang, J., Liu, W., Wei, X., Zhou, J., & Chen, H. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s612495
Saccoliti, F., Patacchini, E., Cara, E., Zarbo, L., Messore, A., Albano, A., Ruggieri, G., Madia, V. N., Scipione, L., Costi, R., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70428 · Cited by 1
Chivite, I., Moraga, E., Sempere, A., Vicens‐Artés, S., Callau, P., Rovira, C., Hurtado, C., Nicolò, A. D., Sánchez-Molina, A., Torres, B., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104158
Tsai, T.-Y., Tsai, C.-S., Huang, S., Wu, T., Chiu, P.-W., Liu, W.-D., Chen, A. P.-L., Lin, K.-Y., & Hung, C.-C. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.108020
BindingDB Entry 50018529: Advances in the development of HIV integrase strand transfer inhibitors.
BindingDB (2024) · UC San Diego · doi:10.7270/q25143gj
Dosing HIV integrase inhibitors with enzyme inducers: Convenience vs . control?
Marzolini, C., & Khoo, S. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70900
Metadata
- Authors
- White, K. L., Osman, N., Cuadra-Foy, E., Brenner, B. G., Shivakumar, D., Campigotto, F., Tsiang, M., Morganelli, P. A., Novikov, N., Lazerwith, S. E., Jin, H., & Niedziela-Majka, A.
- Affiliations
- Gilead Sciences (United States) (US)
- Jewish General Hospital (CA)
- Gilead Sciences, Inc., Foster City, California, USA
- Corresponding author
- White, Kirsten L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2021-04-19
- Volume
- 65
- Issue
- 5
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC8092912
- OpenAlex
- W3134682517
- Cited by
- 33
- References
- 24
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 6 · 2023: 8 · 2022: 4 · 2021: 3
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- bictegravir, HIV-1 integrase, integrase inhibitors, integrase-DNA complex, drug washout, drug resistance mutations, dolutegravir, drug residence time, antiviral activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.